Teva Wins US Approval for Home Treatment of Agitation in Schizophrenia

Teva secures first-of-its-kind US approval for home use of IGALMI to treat acute agitation in schizophrenia and bipolar patients, lifting company shares by 2.6%.

Teva Wins US Approval for Home Treatment of Agitation in Schizophrenia
Photo-illustration WireIsrael: AI Generated

Teva Pharmaceutical Industries secured a breakthrough approval from the US Food and Drug Administration (FDA) for the home use of IGALMI, less than three weeks after acquiring the treatment. The landmark decision marks the first time US regulators have approved a self-administered treatment for acute agitation associated with schizophrenia or bipolar disorder outside of a medical facility.

Following the regulatory announcement, Teva shares rose 2.6 percent on the Tel Aviv Stock Exchange. While the approval significantly broadens the commercial potential for the medication, the company has not yet disclosed revenue projections or an official launch timeline.

Regulatory Milestone and Acquisition Strategy

IGALMI was previously restricted to acute agitation treatment under direct medical supervision within clinical settings. The expanded indication now permits prescribed home use by adults managing schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

The regulatory pathway traces back to a filing submitted to the FDA in January 2026, months before Teva acquired the advanced-stage medical asset in late October. By purchasing the drug late in its regulatory review process, Teva secured a near-term milestone without undertaking early-stage pharmaceutical development. Financial terms of the acquisition were not disclosed.

Market Potential and Clinical Basis

Teva data indicates that between 25 percent and 40 percent of patients suffering from these psychiatric conditions experience acute agitation episodes characterized by severe tension, restlessness, and hyperactivity. In escalated scenarios, up to 21 percent of these episodes result in emergency room visits or hospital admissions.

Previous US-approved pharmaceutical options for such episodes strictly required institutional administration or close clinical oversight. The authorization of a home-treatment alternative is projected to alter care models for eligible patients while easing burdens on families and caregivers.

The FDA approval relies on safety and efficacy data gathered from a 12-week Phase 3 clinical trial involving 102 patients.

Related News